Brief: Finch Therapeutics Group Inc Announces Takeda To Accelerate Leadership Role In Fin-524 Ulcerative Colitis Development Program
10/08/2021 12:51
Aug 10 (Reuters) - Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS GROUP INC - ANNOUNCES TAKEDA TO
ACCELERATE
LEADERSHIP ROLE IN FIN-524 ULCERATIVE COLITIS DEVELOPMENT
PROGRAM
* FINCH THERAPEUTICS GROUP INC - TO TRANSFER FIN-524 PROGRAM
TO
TAKEDA FOR CLINICAL DEVELOPMENT
* FINCH THERAPEUTICS GROUP INC - FINCH AND TAKEDA TO
CONTINUE
DISCOVERY EFFORTS TARGETING CROHN'S DISEASE
Source text for Eikon: ID:nGNX6MztcN
Further company coverage: FNCH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp